脐血干细胞治疗视神经损伤的临床观察

目的:观察脐血间充质干细胞治疗视神经损伤的安全性和疗效。方法:搜集2010年12月至2011年9月来我院住院的视神经损伤患者23人,其中男15人,女8人,年龄在5-77岁之间,平均年龄30.1岁,其中原发性视神经萎缩12人,遗传性Lebers病5人,视神经发育不良者1人,视隔发育不良者2人,视网膜色素变性者3人。治疗前后进行各项指标检测,包括谷丙转氨酶、谷草转氨酶、尿素氮、肌酐、血糖、甘油三酯、胆固醇、乙肝表面抗原、凝血酶原时间、部分凝血酶原时间、甲胎球蛋白、癌胚抗原检查,眼科检查视力、眼压、闪光型视觉诱发电位等,采用脐血间充质干细胞对收集的23位视神经损伤患者进行治疗,每次(给药间隔3-5天,每次给予5*107个干细胞)。对视神经损伤患者治疗前后检测实验室指标及闪光型视觉诱发电位的进行对比,分析脐血间充质干细胞对视神经损伤的治疗安全性及效果。结果:脐血间充质干细胞治疗前后实验室指标、眼压无显著性差异,视力、闪光型视觉诱发电位的潜时、波幅变化明显。结论:脐血间充质干细胞移植治疗视神经损伤患者的过程安全可靠;脐血间充质干细胞移植治疗视神经损伤患者视力、闪光型视觉诱发电位均有改善。

Objective：Observe the safety and curative effect of umbilical cord-derived stem cell（UC-MSC） therapy for optic nerve damage（OND）.Methods：Collected in December 2010 to September 2011 ONDto our hospital 23 patients in our hospital between Dec 2010 and Sep 2011,15 male and 8 female,between 5 and 77 years,and average age was 30.1 years old,with 12 primary optic nerve atrophy（ONA） patients,5 Leber Hereditary Optic Neuropathy（LHON） patients,1 Optic Nerve Hypoplasia（ONH） patient,2 Septo Optic Dysplasia（SOD） patients,and 3 Retinitis Pigmentosa（RP） patients.We detected every indicator before and after treatments,included ALT,AST,BUN,creatinine,blood sugar,TG,cholesterol,HBsAg,PT,partial thromboplastin time（APIT）,AFP,CEA and ophthalmologic examination： visual acuity（VA）,intraocular pressure（IOP）,the Flash visual evoked potential（F-VEP）.Using umbilical cord-derived mesenchymal stem cell（UC-MSC）treated for collected 23 optic nerve damage patients in 4 treatments,each treatment gave 5 × 107 stem-cells apart 3 to 5 days.By comparing the Flash visual evoked potential（F-VEP）results before and after treatments for OND patients,analyse the treatment effect of UCMSC.Result：There was no significant difference in laboratory indicators and IOP,however,there were marked difference in VA,latency and amplitude of F-VEP before and after treatments.Conclusion：The procedure of umbilical cord blood stem cell treatment for OND patients is safe and reliable.Umbilical cord-derived mesenchymal stem cell transplantation is able to improve ONI patients＇ VA,F-VEP.